Bosulif (bosutinib) interferes with the expansion of some cancer cells.
Bosulif is employed to treat a kind of blood cancer known as metropolis body positive chronic myelogenous cancer(CML).
Bosulif is sometimes given when alternative similar medications are tried while not success.
Submit your review
Get emergency medical help if you have signs of an allergic reaction to Bosulif: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using Bosulif and call your doctor at once if you have:
severe or ongoing nausea, vomiting, stomach pain, or diarrhea;
swelling in your hands or feet, rapid weight gain;
low blood cell counts - fever, chills, flu-like symptoms, swollen gums, mouth sores, skin sores, rapid heart rate, pale skin, easy bruising, unusual bleeding, feeling light-headed;
liver problems - nausea, upper stomach pain, itching, tiredness, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
swelling or fluid build-up in the lungs - anxiety, sweating, pale skin, severe shortness of breath, pain when you breathe, feeling short of breath while lying down, wheezing, gasping for breath, cough with foamy mucus, chest pain, fast or uneven heart rate.
Your cancer treatments may be delayed if you have certain side effects.
Common Bosulif side effects may include:
nausea, vomiting, diarrhea, stomach pain;
pale skin, bruising or bleeding.
500 mg orally once a day with food Duration of therapy: Until disease progression or patient intolerance Comments: If a dose is missed beyond 12 hours, the patient should skip the dose and take the usual prescribed dose on the following day. Use: Treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.